Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

JC Colet, AS Mainar… - Journal of …, 2023 - becarispublishing.com
Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation
(NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study …

Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain

GB Esquivias, GE Albaladejo, JL Zamorano… - Revista Española de …, 2015 - Elsevier
Introduction and objectives Cost-effectiveness analysis of apixaban (5 mg twice daily) vs
acenocoumarol (5 mg/day) in the prevention of stroke in patients with nonvalvular atrial …

Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world …

SV Ramagopalan, A Sicras-Mainar… - Journal of …, 2019 - becarispublishing.com
Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …

Latin American clinical epidemiology network series–Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with …

F Lanas, C Castro, C Vallejos, L Bustos… - Journal of Clinical …, 2017 - Elsevier
Objective Nonvalvular atrial fibrillation (NVAF) is a risk factor for ischemic stroke and
systemic embolism. New oral anticoagulants are currently available. The objective of this …

Estimation of the effectiveness of apixaban in non valvular atrial fibrillation in anticoagulant suitable population in Argentina

MA Giorgi, C Caroli, P Micone, ND Giglio… - European Heart …, 2013 - academic.oup.com
Purpose: To estimate the effectiveness of apixaban relative to warfarin in NVAF
anticoagulation suitable population in Argentina. Methods: A literature review was …

[HTML][HTML] A systematic literature review on the cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation

C Pinyol, JM Cepeda, I Roldan, V Roldan… - Cardiology and …, 2016 - Springer
Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Comparison of Hospital Length of Stay and Costs between Non-Valvular Atrial Fibrillation Patients Treated with Either Apixaban or Warfarin

L Xie, L Vo, A Keshishian, K Price, P Singh… - … Quality and Outcomes, 2015 - Am Heart Assoc
Background: Patients with non-valvular atrial fibrillation (NVAF) have an increased risk of
stroke and are often treated with oral anticoagulants (ie warfarin). However, apixaban, a …

Cost-effectiveness analysis of apixaban versus rivaroxaban for prevention of stroke in patients with non-valvular atrial fibrillation in Spain

CC Fontcuberta, GE Albaladejo… - Value in …, 2013 - valueinhealthjournal.com
Objectives To assess the cost-effectiveness of apixaban versus rivaroxaban in the
prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in Spain. Methods …

Application of new French guidelines for economic evaluations: A cost-effectiveness analysis of apixaban in patients with non-valvular atrial fibrillation in France

I Durand-Zaleski, FE Cotté, T Lanitis… - Value in …, 2013 - valueinhealthjournal.com
Objectives To evaluate the cost-effectiveness of apixaban in the prevention of stroke in
patients with non-valvular atrial fibrillation (NVAF) from a French payer perspective. Methods …

Cost effectiveness analysis of apixaban compared to oral anticoagulants in the prevention of thromboembolic events in patients with non-valvular atrial fibrillation in …

M Garita-Aguilar, M Peralta-Acon… - Value in …, 2015 - valueinhealthjournal.com
BACKGROUND Atrial fibrillation (AF) is associated with development of thromboembolic
events [1]. The standard therapy used in patients with non-valvular atrial fibrillation (NVAF) …